Expanded Access With COVID Therapeutics Were ‘Worst-Case Scenario’ For Informed Consent

 
• By Sue Sutter

High-profile programs, such as convalescent plasma, also created public confusion about role of preapproval access and highlighted the importance of prospectively planning for reliable data collection, experts said at the DIA global annual meeting.

Foot in door
Expanded access programs allow patients to get a foot in the door for investigational therapies when clinical trials are not available. • Source: Alamy

More from Rare Diseases

More from Pink Sheet